.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Deloitte
Medtronic
Harvard Business School
Baxter
Chinese Patent Office
Federal Trade Commission
Farmers Insurance
Mallinckrodt

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,741,269

« Back to Dashboard

Which drugs does patent 7,741,269 protect, and when does it expire?


Patent 7,741,269 protects BYDUREON, BYDUREON PEN, BYETTA, BYDUREON BCISE, and FARXIGA, and is included in four NDAs. There has been one Paragraph IV challenge on Byetta.

This patent has seventy-five patent family members in seventeen countries.

Summary for Patent: 7,741,269

Title:Exendins and exendin agonists for weight reduction and obesity
Abstract:Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Inventor(s): Young; Andrew A. (San Diego, CA), Bhavsar; Sunil (San Diego, CA), Gedulin; Bronislava (San Diego, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/895,909
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca AbBYDUREONexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-001Jan 27, 2012RXYesYes► Subscribe► SubscribeREDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE► Subscribe
Astrazeneca AbBYDUREON PENexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-002Feb 28, 2014RXYesYes► Subscribe► SubscribeREDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE► Subscribe
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-001Apr 28, 2005RXYesYes► Subscribe► SubscribeSTIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE► Subscribe
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-001Apr 28, 2005RXYesYes► Subscribe► SubscribeUSE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT► Subscribe
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-001Apr 28, 2005RXYesYes► Subscribe► SubscribeTREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE► Subscribe
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-002Apr 28, 2005RXYesYes► Subscribe► SubscribeSTIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE► Subscribe
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-002Apr 28, 2005RXYesYes► Subscribe► SubscribeUSE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT► Subscribe
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-002Apr 28, 2005RXYesYes► Subscribe► SubscribeTREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE► Subscribe
Astrazeneca AbBYDUREON BCISEexenatideSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS209210-001Oct 20, 2017RXYesYes► Subscribe► SubscribeREDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE► Subscribe
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-001Jan 8, 2014RXYesNo► Subscribe► SubscribeREDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,741,269

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,419,952Use of exendins and agonists thereof to treat diabetes► Subscribe
8,288,338Exendin and exendin agonists for eating disorders► Subscribe
7,858,740Exendin agonist compounds► Subscribe
7,138,375Use of exendins and agonists thereof for lowering plasma lipid► Subscribe
7,297,761Pharmaceutical compositions containing exendins► Subscribe
6,858,576 Methods for regulating gastrointestinal motility► Subscribe
8,026,210Exendins and exendin agonist analogs to regulate gastrointestinal motility► Subscribe
7,220,721Exendin agonist peptides► Subscribe
7,521,423Exendin pharmaceutical compositions► Subscribe
7,157,555Exendin agonist compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,741,269

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria304864► Subscribe
Austria381939► Subscribe
Austria383867► Subscribe
Austria417622► Subscribe
Austria493998► Subscribe
Australia1404699► Subscribe
Australia1458899► Subscribe
Australia2003200129► Subscribe
Australia2003203955► Subscribe
Australia2006225176► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Fuji
Dow
Medtronic
Covington
US Department of Justice
UBS
Novartis
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot